Photodynamic therapy (PDT) for the inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be a valuable therapy for the treatment of coronavirus disease 2019 (COVID-19) disease. The spread of the SARS-CoV-2 virus has caused the COVID-19 pandemic, resulting in the death of many people worldwide due to the lack of effective treatments. FDA has recently approved two mRNA-based vaccines for emergency use, but still vaccine supply is limited. Therefore, it is imperative to discover new therapeutic strategies for the management of COVID-19 patients. PDT has been used to deactivate microorganisms for many years and might be an effective and promising therapy for COVID-19 patients. The PDT procedure is composed of a photosensitizer, light, and oxygen, which generate a local spurt of reactive oxygen species that can inactivate enveloped viruses and microorganisms. PDT is a safe, faster, cost-effective, and simple method to inactivate microorganisms. In addition, there have been no reports of resistance, unlike other antibiotics and antiviral drugs. This review aims to update the advancement of PDT and the findings could attract clinical attention in future clinical trials.